[en] We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes compared to those receiving intensive chemotherapy (IC). We conducted a phase 3 randomized trial to compare DEC (10-day schedule) to IC (3+7) in older fit AML patients. HRQoL was a secondary endpoint, and it was assessed with the EORTC QLQ-C30 and the QLQ-ELD14. The following scales were a priori selected for defining the primary endpoint: physical and role functioning, fatigue, pain, and burden of illness. HRQoL was assessed at baseline, at regeneration from cycle 2, and at 6 and 12 months after randomization, and also prior to allo-HSCT and 100 days after transplantation. Overall, 606 patients underwent randomization. At 2 months, the risk of HRQoL deterioration was lower in the DEC arm than in the 3+7 arm (76% [95% CI, 69 to 82] v 88% [95% CI, 82 to 93]; odds ratio, 0.43 [95% CI, 0.24 to 0.76], P=.003). No statistically significant HRQoL differences were observed between treatment arms at the long-term evaluation combining assessments at 6 and 12 months. HRQoL deteriorations between baseline and post-allo-HSCT were observed in both arms. However, these deteriorations were not clinically meaningful in patients randomized to DEC, while this was the case for those in the 3+7 arm, in four out of the five primary HRQoL scales. Our HRQoL findings suggest that lower-intensity treatment with DEC, may be preferable to current standard IC (3+7), in fit older AML patients. ClinicalTrials.gov (NCT02172872).
Disciplines :
Hematology
Author, co-author :
Efficace, Fabio; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
Sasaki, K, Ravandi, F, Kadia, TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. Cancer 127:12 (2021), 2049–2061.
Kantarjian, H, Kadia, T, DiNardo, C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J, 11(2), 2021, 41.
Rosko, AE, Cordoba, R, Abel, G, Artz, A, Loh, KP, Klepin, HD, Advances in management for older adults with hematologic malignancies. J Clin Oncol 39:19 (2021), 2102–2114.
Kantarjian, HM, Thomas, XG, Dmoszynska, A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:21 (2012), 2670–2677.
Dombret, H, Seymour, JF, Butrym, A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:3 (2015), 291–299.
DiNardo, CD, Jonas, BA, Pullarkat, V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:7 (2020), 617–629.
Wei, AH, Montesinos, P, Ivanov, V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:24 (2020), 2137–2145.
Pratz, KW, Panayiotidis, P, Recher, C, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J, 12(4), 2022, 71.
Dohner, H, Weisdorf, DJ, Bloomfield, CD, Acute myeloid leukemia. N Engl J Med 373:12 (2015), 1136–1152.
Lübbert, M, Wijermans, PW, Kicinski, M, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol 10:11 (2023), e879–e889.
Sekeres, MA, Stone, RM, Zahrieh, D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18:4 (2004), 809–816.
Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:5 (1993), 365–376.
Wheelwright, S, Darlington, AS, Fitzsimmons, D, et al. International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer. Br J Cancer 109:4 (2013), 852–858.
Fayers, PM, Aaronson, NK, Bjordal, K, Groenvold, M, Curran, D, Bottomley, A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd, 2001, European Organisation for Research and Treatment of Cancer.
Giesinger, JM, Efficace, F, Aaronson, N, et al. Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review. Value Health 24:4 (2021), 585–591.
Stauder, R, Lambert, J, Desruol-Allardin, S, et al. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: literature review and landscape analysis. Eur J Haematol 104:5 (2020), 476–487.
Young, T, De Haes, H, Curran, D, et al. EORTC Guidelines for Assessing Quality of Life in Clinical Trials. 2002, EORTC Quality of Life Group Publication https://www.eortc.org/app/uploads/sites/2/2018/02/clinical_trials__guidelines_qol.pdf. (Accessed 8 February 2023)
Calvert, M, Blazeby, J, Altman, DG, Revicki, DA, Moher, D, Brundage, MD, CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:8 (2013), 814–822.
Osoba, D, Rodrigues, G, Myles, J, Zee, B, Pater, J, Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:1 (1998), 139–144.
Neuendorff, NR, Gagelmann, N, Singhal, S, et al. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia-a joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. J Geriatr Oncol, 14(3), 2023, 101406.
Loh, KP, Abdallah, M, Kumar, AJ, Neuendorff, NR, Dahiya, S, Klepin, HD, Health-related quality of life and treatment of 0lder adults with acute myeloid leukemia: a Young International Society of Geriatric Oncology review paper. Curr Hematol Malig Rep 14:6 (2019), 523–535.
Lin, RJ, Artz, AS, Allogeneic hematopoietic cell transplantation for older patients. Hematology Am Soc Hematol Educ Program 2021:1 (2021), 254–263.
Bernhard, J, Cella, DF, Coates, AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:5-7 (1998), 517–532.
Buckley, SA, Halpern, AB, Othus, M, Jimenez-Sahagun, D, Walter, RB, Lee, SJ, Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leuk Lymphoma 61:5 (2020), 1158–1167.
Basch, E, Toward patient-centered drug development in oncology. N Engl J Med 369:5 (2013), 397–400.
Bryant, AL, Drier, SW, Lee, S, Bennett, AV, A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. Leuk Res 70 (2018), 106–116.
Efficace, F, Kemmler, G, Vignetti, M, Mandelli, F, Molica, S, Holzner, B, Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 44:11 (2008), 1497–1506.
Cannella, L, Caocci, G, Jacobs, M, Vignetti, M, Mandelli, F, Efficace, F, Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned?. Crit Rev Oncol Hematol 96:3 (2015), 542–554.
Sekeres, MA, Guyatt, G, Abel, G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv 4:15 (2020), 3528–3549.
